Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Nicotinamide Riboside Supplementation for Decreasing Inflammation in Middle-Aged and Older Adults

Award Number: F31HL154782
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 08/01/2020
PERIOD OF PERFORMANCE END DATE: 07/31/2023

Group Awards By:

View Award Description

Nicotinamide Riboside Supplementation for Decreasing Inflammation in Middle-Aged and Older Adults - CANDIDATE: Kaitlin A. Freeberg is a second-year graduate student in the Department of Integrative Physiology at the University of Colorado (CU) Boulder. Ms. Freeberg proposes to gain novel research training by taking advantage of opportunities provided by a recently initiated NIH R01-funded clinical trial of the nutraceutical compound, nicotinamide riboside (NR), for decreasing systolic blood pressure (SBP) and arterial stiffness in middle-aged and older adults with above-normal SBP. She seeks to perform additional experiments within this clinical trial by leveraging blood samples collected under the parent grant to determine the efficacy and mechanisms of action of NR for decreasing inflammation in this subject population. Her immediate goal is to gain the fundamental clinical and translational research experience and professional skills necessary to perform independent biomedical research. Her long-term goal is to become an academic scientist investigating creative strategies for improving cardiovascular (CV) function and health. CAREER DEVELOPMENT PLAN: Ms. Freeberg’s career development consists of: 1) gaining mentored experience conducting a randomized, placebo-controlled, double-blind, phase IIa clinical trial; 2) learning state-of-the-art biochemical and cellular techniques and molecular analyses to strengthen her translational research skills; 3) training in biostatistics and bioinformatics; 4) further developing her professional skills through formal coursework and participation in weekly laboratory journal clubs, university seminars, and national scientific conferences; and 5) interacting regularly with her mentoring team. ENVIRONMENT: Ms. Freeberg’s training plan environment is exceptional. The sponsor, Dr. Seals, has >30 years of NIH-funded research experience and a successful record of mentoring trainees in translational research to improve CV function in groups with increased CV disease (CVD) risk. Co- mentor Dr. You is a biostatistician at the CU Anschutz Medical Campus. Co-mentor Dr. Ziemba, who directs our biochemistry core research and training program, has extensive experience designing and performing innovative cellular and molecular translational research experiments. RESEARCH: Above-normal SBP and arterial stiffness increase CVD risk. Increases in SBP and arterial stiffness are mediated, in part, by chronic inflammation. NR supplementation is a promising healthspan- extending strategy to reduce inflammation, SBP and arterial stiffness in adults with above-normal SBP. This research will investigate the efficacy of NR treatment for reducing chronic inflammation (Aim 1) and identify treatment-induced changes in molecular signaling pathways via targeted plasma metabolomics analyses (Aim 2) that directly inhibit inflammatory cytokine production (Aim 3). Changes in these mechanistic processes will then be related to changes in SBP and arterial stiffness.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$1,716 )
2024	2022	THE REGENTS OF THE UNIVERSITY OF COLORADO	3100 MARINE ST	BOULDER	CO	80309	BOULDER	USA	Cardiovascular Diseases Research	000	3	6/24/2024	NON-COMPETING CONTINUATION	-$1,716
														Subtotal = -$1,716

Issue Date FY: 2022 ( Subtotal = $38,875 )
2022	2022	REGENTS OF THE UNIVERSITY OF COLORADO, THE	3100 MARINE ST STE 481 572 UCB	BOULDER	CO	80309	BOULDER	USA	Cardiovascular Diseases Research	000	3	6/19/2022	NON-COMPETING CONTINUATION	$38,875
														Subtotal = $38,875

Issue Date FY: 2021 ( Subtotal = $38,159 )
2021	2021	REGENTS OF THE UNIVERSITY OF COLORADO, THE	3100 MARINE ST STE 481 572 UCB	BOULDER	CO	80309	BOULDER	USA	Cardiovascular Diseases Research	000	2	8/20/2021	NON-COMPETING CONTINUATION	$38,159
														Subtotal = $38,159

Issue Date FY: 2020 ( Subtotal = $37,643 )
2020	2020	REGENTS OF THE UNIVERSITY OF COLORADO, THE	3100 MARINE ST STE 481 572 UCB	BOULDER	CO	80309	BOULDER	USA	Cardiovascular Diseases Research	000	1	7/9/2020	NEW	$37,643
														Subtotal = $37,643

Grand Total All Awards = $112,961

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Nicotinamide Riboside Supplementation for Decreasing Inflammation in Middle-Aged and Older Adults

Award Number: F31HL154782

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 08/01/2020

PERIOD OF PERFORMANCE END DATE: 07/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer